CDK7 and mature T-cell and NK-cell non-Hodgkin lymphoma: To determine whether this subgroup of patients could benefit from a CDK7 targeting approach, we analysed the expression of CDK7 in 18 PTCL-NOS and 17 ALCL-ALKneg cases.